ATE517100T1 - Pyrrolidinarylether als nk3-rezeptorantagonisten - Google Patents

Pyrrolidinarylether als nk3-rezeptorantagonisten

Info

Publication number
ATE517100T1
ATE517100T1 AT08786547T AT08786547T ATE517100T1 AT E517100 T1 ATE517100 T1 AT E517100T1 AT 08786547 T AT08786547 T AT 08786547T AT 08786547 T AT08786547 T AT 08786547T AT E517100 T1 ATE517100 T1 AT E517100T1
Authority
AT
Austria
Prior art keywords
pyrrolidinaryl
ether
receptor antagonists
antagonists
receptor
Prior art date
Application number
AT08786547T
Other languages
English (en)
Inventor
Philippe Jablonski
Kenichi Kawasaki
Henner Knust
Anja Limberg
Matthias Nettekoven
Hasane Ratni
Claus Riemer
Xihan Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE517100T1 publication Critical patent/ATE517100T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT08786547T 2007-08-07 2008-07-29 Pyrrolidinarylether als nk3-rezeptorantagonisten ATE517100T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113942 2007-08-07
PCT/EP2008/059908 WO2009019163A1 (en) 2007-08-07 2008-07-29 Pyrrolidine aryl-ether as nk3 receptor antagonists

Publications (1)

Publication Number Publication Date
ATE517100T1 true ATE517100T1 (de) 2011-08-15

Family

ID=39865446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08786547T ATE517100T1 (de) 2007-08-07 2008-07-29 Pyrrolidinarylether als nk3-rezeptorantagonisten

Country Status (19)

Country Link
US (1) US8012998B2 (de)
EP (1) EP2185540B1 (de)
JP (1) JP2010535733A (de)
KR (1) KR101167774B1 (de)
CN (1) CN101778837A (de)
AR (1) AR067808A1 (de)
AT (1) ATE517100T1 (de)
AU (1) AU2008285718A1 (de)
BR (1) BRPI0815658A2 (de)
CA (1) CA2695211A1 (de)
CL (1) CL2008002293A1 (de)
ES (1) ES2367464T3 (de)
IL (1) IL203363A (de)
MX (1) MX2010001080A (de)
PE (1) PE20090898A1 (de)
RU (1) RU2010106974A (de)
TW (1) TW200916456A (de)
WO (1) WO2009019163A1 (de)
ZA (1) ZA201000676B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008290634B2 (en) * 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
AU2010209825A1 (en) 2009-01-30 2011-08-11 F. Hoffmann-La Roche Ag Piperidine derivatives as NK3 receptor antagonists
US8318759B2 (en) * 2009-02-18 2012-11-27 Hoffmann-La Roche Inc. Pyrrolidine derivatives as NK3 receptor antagonists
US8394834B2 (en) 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
JP2013508350A (ja) * 2009-10-20 2013-03-07 ファイザー・インク ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール
US8507535B2 (en) 2010-07-07 2013-08-13 Hoffmann-La Roche Inc. Methyl-pyrrolidine ether derivatives
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
CA3015702A1 (en) 2015-09-02 2017-03-09 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
CN105399661A (zh) * 2015-12-14 2016-03-16 华东师范大学 2,6-二溴甲基吡啶的制备方法
EP3456716A4 (de) * 2016-05-09 2019-11-06 Nippon Soda Co., Ltd. Ringförmige amidverbindung und schädlingsbekämpfungsmittel
BR112019016827A2 (pt) 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
JP7185633B2 (ja) 2017-02-17 2022-12-07 トレベナ・インコーポレイテッド ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU506399B2 (en) 1975-12-30 1980-01-03 Showa Denko Kabushiki Kaisha 3-(2-aryl-2-propyl) ureas
IN148482B (de) 1977-06-03 1981-03-07 Pfizer
GB9321557D0 (en) 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69434063D1 (de) 1993-12-29 2004-11-11 Merck Sharp & Dohme Substituierte Morpholinderivate und ihre Verwendung als therapeutische Mittel
IL112778A0 (en) 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
GB9714129D0 (en) * 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1192952A3 (de) 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
NZ537330A (en) * 2002-05-31 2007-04-27 Takeda Chemical Industries Ltd Piperidine derivative, process for producing the same, and use
HRP20070471T3 (hr) 2003-07-03 2007-11-30 F. Hoffmann - La Roche Ag Dvojni nk1/nk3 antagonisti za liječenje shizofrenije
US7468437B2 (en) * 2003-09-30 2008-12-23 Merck & Co., Inc. Phenyl pyrrolidine ether tachykinin receptor antagonists
CA2552965A1 (en) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited Carboxamide derivative and use thereof
US7138423B2 (en) * 2004-07-20 2006-11-21 Bristol-Myers Squibb Company Arylpyrrolidine derivatives as NK-1 /SSRI antagonists
KR100939347B1 (ko) 2005-07-20 2010-01-29 (주)카이로드 광학적으로 순수한 (ｓ)-3-히드록시 피롤리딘의 제조방법

Also Published As

Publication number Publication date
ES2367464T3 (es) 2011-11-03
ZA201000676B (en) 2010-10-27
US20090042896A1 (en) 2009-02-12
AR067808A1 (es) 2009-10-21
BRPI0815658A2 (pt) 2015-02-18
RU2010106974A (ru) 2011-09-20
JP2010535733A (ja) 2010-11-25
PE20090898A1 (es) 2009-07-13
MX2010001080A (es) 2010-03-01
US8012998B2 (en) 2011-09-06
CL2008002293A1 (es) 2009-05-29
WO2009019163A1 (en) 2009-02-12
KR20100045502A (ko) 2010-05-03
IL203363A (en) 2013-03-24
KR101167774B1 (ko) 2012-07-24
AU2008285718A1 (en) 2009-02-12
EP2185540B1 (de) 2011-07-20
TW200916456A (en) 2009-04-16
CA2695211A1 (en) 2009-02-12
EP2185540A1 (de) 2010-05-19
CN101778837A (zh) 2010-07-14

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
ATE519738T1 (de) Pyrrolidinarylether als nk3-rezeptorantagonisten
EP2350060A4 (de) Melanocortin-rezeptor-agonisten
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
EP2150115A4 (de) Cyclopropylpyrrolidinorexin-rezeptorantagonisten
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
DK2009992T3 (da) Il-8 receptor-antagonister
EP1981902A4 (de) Nogo-rezeptorantagonisten
BRPI0910592A2 (pt) antagonistas de receptor 2 de somatostatina
DK2129654T3 (da) Antagonister af glucagonreceptoren
IL225978A0 (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE537151T1 (de) Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
BRPI0815658A2 (pt) Aril-éter pirrolidina como antagonistas do receptor nk3
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
BRPI0810926A2 (pt) Antagonista de crig
BRPI0817835A2 (pt) Antagonistas cgrp
EP2254413A4 (de) Imidazobenzazepin-cgrp-rezeptorantagonisten
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
BRPI0918004A2 (pt) antagonistas de glucagon
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2185540

Country of ref document: EP